Glaxosmithkline's Double Boost On Cancer Treatments [Edition 2]
Evening Standard - London › July 09, 2009
Linked as:
Summary
PHARMA giant GlaxoSmithKline had a double injection of health today, when the World Health Organisation approved its cervical cancer vaccine Cervarix and the British medical watchdog said it would reconsider its block on breast cancer treatment Tyverb's use in the National Health Service.
The WHO's decision gives the UK's biggest pharma firm the green light to sell Cervarix to UN agencies for use in developing countries, where 80% of the 280,000 annual deaths from cervical cancer occur every year. The verdict could also boost GSK's application for Cervarix's approval in the US.See the full content of this document
Extract
Glaxosmithkline's Double Boost On Cancer Treatments [Edition 2]
Meanwhile, the National Ins...
See the full content of this document
Sponsored links
